Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "pdufa"

Natpara PDUFA date approaches

To screen ETFs by asset class, performance, yield and more, check out the ETF Hub. Seeking Alpha, 4 hours ago

13 images for pdufa

FDA News, 1 month ago
Regulatory Affairs Professionals Society, 1 month ago
MedPage Today, 2 months ago
ABC News 4 Charleston, 2 months ago
Scottrade, 2 months ago
Motley Fool, 3 months ago
Seeking Alpha, 4 months ago
Fierce Drug Delivery, 4 months ago
ABC News 4 Charleston, 4 months ago
Nasdaq, 4 months ago

Bearish behavior from AEterna Zentaris ahead of PDUFA

News Editor Nano cap AEterna Zentaris (AEZS -19.8%) plummets on a 3x surge in volume. Shares are down 42% from the September 2 peak of $1.54 and 34% from Friday's close of $1.34. The last three down moves have been on higher volume. November 5 ...
 Seeking Alpha1 week ago

Salix Pharmaceuticals : TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea

Study Results Presented at the American College of Gastroenterology (ACG) Scientific Meeting in Philadelphia on October 21 st Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that Dr. Anthony Lembo of Beth Israel ...
 4 Traders9 hours ago Salix Pharmaceuticals, Ltd.???s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea  BioSpace2 hours ago Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea  TMC Net8 hours ago
[x]  

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib

lenvatinib Treatment for Thyroid Cancer Tokyo -- October 15, 2014 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application ...
 Drugs.com12 hours ago U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome  Stockwatch6 days ago FDA Accepts Pfizer's Palbociclib New Drug Application for Priority Review  PharmaceuticalProcessing6 days ago Pfizer's NDA for Palbociclib accepted for US FDA's priority review for first-line therapy in combination with letrozole in postmenopausal women with breast cancer  PredictWallStreet1 week ago
[x]  

Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension

SAN DIEGO "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submissions from sponsors to identify and designate drug candidates that could potentially treat rare diseases to help advance the evaluation ...
 Bio-Medicine17 hours ago Horizon Pharma's Actimmune Gets Orphan Drug Designation - Analyst Blog  Zacks.com2 weeks ago Orphan status for Horizon Pharma's Actimmune in Friedreich's ataxia04-10-2014  Pharma Letter2 weeks ago MABVAX THERAPEUTICS : Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma  4 Traders2 weeks ago
[x]  

Valeant Pharmaceuticals International's (VRX) CEO Mike Pearson on Q3 2014 Results - Earnings Call Transcript

Operator Good morning. My name is Keith, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Valeant Third Quarter 2014 Earnings Conference Call. All lines have been placed on mute to prevent any ...
 Seeking Alpha23 hours ago

Merrill Lynch's 5 Destroyed Biotech Stocks With 100% or More Upside Potential

While Friday was a welcome relief for shell-shocked stock investors, much of the damage that has been inflicted since the start of the quarter is still weighing on some top biotech stocks. A new report from Merrill Lynch highlights five biotechs ...
 24/7 Wall St1 day ago

Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small...

Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer NSCLC By a News Reporter-Staff News Editor at Pharma Business Week Bristol-Myers ...
 Pharmacy Choice1 day ago BMS Withdraws Combination NDA, Vows to Pursue Daclatasvir Approval  Genetic Engineering News2 weeks ago BMS Launches Cancer-Combo Collaborations with Novartis, MD Anderson  Genetic Engineering News2 weeks ago Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies  Morningstar.com2 weeks ago
[x]  

FirstWord Lists Key pharma and biotech events to watch...to year-end

2014 may be approaching its conclusion but there is a catalogue of key events set to occur among the large cap pharmaceutical and biotech players over the next two and half months. Monday ( October 20 ) could see Novo Nordisk gain approval for ...
 FirstWord Pharma2 days ago
Nasdaq

Amarantus seeks US FDA orphan drug status for MANF to treat retinitis pigmentosa

Amarantus Bioscience Holdings, a biotechnology company focussed on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that it has applied to the US Food & Drug ...
 PharmaBiz3 days ago Amarantus Bioscience Holdings, Inc. (AMBS: OTCQB) | Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa  Pink Sheets5 days ago Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa  Pettinga Financial Advisors5 days ago Amarantus BioSciences, Inc. Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa  BioSpace5 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less